Yahoo · Sep 25, 2026
2 Falling Stocks Call Traders Are Targeting Today
Call traders are targeting META and VTGN
VT
NASDAQ · VTGN
VistaGen Therapeutics, Inc.
Healthcare · Biotechnology
$0.21
Down-$0.00 (-0.97%)
Updated Oct 15, 2026, 2:49 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 129.29M
- P/E ratio
- -2.27
- Dividend yield
- 0.00%
- 52-week range
- $0.20 – $5.14
- Volume
- 989.74K
- Avg. volume
- 683.98K
Price performance · VTGN
VTGN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 14, 2026
VTGN closed at $0.21 after 21 trading sessions, down 10.41% for the selected period.
- Last close
- $0.21
- Period change
- -10.41%
- Period low
- $0.21
- Period high
- $0.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 14, 2026 | $0.206 | $0.2111 | $0.20 | $0.2066 | 989.74K |
| Oct 13, 2026 | $0.2233 | $0.225 | $0.212 | $0.2148 | 1.04M |
| Oct 12, 2026 | $0.236 | $0.236 | $0.221 | $0.2266 | 739.9K |
| Oct 9, 2026 | $0.2398 | $0.2445 | $0.236 | $0.2361 | 404.86K |
| Oct 8, 2026 | $0.2463 | $0.2499 | $0.2366 | $0.2462 | 959.3K |
| Oct 7, 2026 | $0.2521 | $0.2567 | $0.2424 | $0.2471 | 780.42K |
| Oct 6, 2026 | $0.2654 | $0.2696 | $0.2506 | $0.2506 | 1.6M |
| Oct 5, 2026 | $0.28 | $0.2839 | $0.263 | $0.2632 | 1.92M |
| Oct 2, 2026 | $0.2837 | $0.2999 | $0.2778 | $0.281 | 1.25M |
| Oct 1, 2026 | $0.3077 | $0.314 | $0.2793 | $0.2826 | 2.03M |
| Sep 30, 2026 | $0.2896 | $0.318 | $0.284 | $0.3078 | 2.43M |
| Sep 29, 2026 | $0.288 | $0.3049 | $0.2829 | $0.298 | 2.03M |
| Sep 28, 2026 | $0.2702 | $0.319 | $0.268 | $0.297 | 6.03M |
| Sep 25, 2026 | $0.2845 | $0.2973 | $0.2641 | $0.273 | 5.57M |
| Sep 24, 2026 | $0.349 | $0.3599 | $0.2701 | $0.295 | 20.47M |
| Sep 23, 2026 | $0.3861 | $0.5476 | $0.3351 | $0.3684 | 574.96M |
| Sep 22, 2026 | $0.246 | $0.267 | $0.2407 | $0.2514 | 6M |
| Sep 21, 2026 | $0.236 | $0.2444 | $0.2325 | $0.233 | 332.12K |
| Sep 18, 2026 | $0.234 | $0.2532 | $0.234 | $0.24 | 718.61K |
| Sep 17, 2026 | $0.2352 | $0.2397 | $0.2323 | $0.2336 | 369.92K |
| Sep 16, 2026 | $0.236 | $0.2398 | $0.226 | $0.2306 | 553.57K |
Latest VTGN news
The latest Smart Investors Daily articles mentioning VTGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VTGN research
Overview
Company profile and research snapshot.
Company profile
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 17, 2025 | Maxim Group | Hold | — |
| Dec 17, 2025 | Jefferies | Hold | — |
| Dec 17, 2025 | William Blair | Market Perform | — |
| Dec 7, 2023 | Jefferies | Buy | — |
| Nov 14, 2023 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 24, 2026
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operat
Yahoo · Sep 24, 2026
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
Vistagen (NASDAQ:VTGN) presented exploratory clinical data for its investigational fasedienol nasal spray at Psych Congress 2026 in New Orleans on September 24, reporting findings from subgroup analyses involving participants with very severe social anxiety disorder. The findings were derived from two randomised, double-blind, placebo-controlled clinical trials and included one post-hoc analysis and one prespecified subgroup analysis.
Benzinga · Sep 24, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen (NASDAQ:SRZN) stock
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
